Amplia Therapeutics Ltd - ATX share price
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Try Veye Free for 7 Days
Expert ASX stock picks, in-depth research & buy/sell signals — free for a full week.
No credit card required
Price Chart (ATX)
TOP ASX STOCKS Worth Watching
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
Discover the Top ASX Stocks to Invest in 2026!
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Latest Article
